Available symptomatic antidementia drugs

Antidementia Drugs Still Available in the U.K.

Internal Medicine News ◽

10.1016/s1097-8690(06)73250-4 ◽

2006 ◽

Vol 39 (7) ◽

pp. 27

Author(s):

JONATHAN GARDNER

Keyword(s):

Antidementia Drugs

Download Full-text

Antidementia Drugs Withstand U.K. Challenge

Clinical Psychiatry News ◽

10.1016/s0270-6644(06)71399-6 ◽

2006 ◽

Vol 34 (5) ◽

pp. 7

Author(s):

JONATHAN GARDNER

Keyword(s):

Antidementia Drugs

Download Full-text

Antidementia Drugs May Prolong Life in Alzheimer's Patients

Family Practice News ◽

10.1016/s0300-7073(08)71024-7 ◽

2008 ◽

Vol 38 (16) ◽

pp. 1-4

Author(s):

MICHELE G. SULLIVAN

Keyword(s):

Antidementia Drugs

Download Full-text

Genetic Editing and Pharmacogenetics in Current And Future Therapy Of Neurocognitive Disorders

Current Alzheimer Research ◽

10.2174/1567205017666200422152440 ◽

2020 ◽

Vol 17 (3) ◽

pp. 238-258 ◽

Cited By ~ 1

Author(s):

Michal Prendecki ◽

Marta Kowalska ◽

Ewa Toton ◽

Wojciech Kozubski

Keyword(s):

Lewy Bodies ◽

Hepatic Metabolism ◽

New Drugs ◽

Glutamate Excitotoxicity ◽

Factors Affecting ◽

Treatment And Prevention ◽

Expression Of Genes ◽

Dementia Risk ◽

Antidementia Drugs ◽

Butyrylcholinesterase Activity

: Dementia is an important issue in western societies, and in the following years, this problem will also rise in the developing regions, such as Africa and Asia. The most common types of dementia in adults are Alzheimer’s Disease (AD), Dementia with Lewy Bodies (DLB), Frontotemporal Dementia (FTD) and Vascular Dementia (VaD), of which, AD accounts for more than half of the cases. : The most prominent symptom of AD is cognitive impairment, currently treated with four drugs: Donepezil, rivastigmine, and galantamine, enhancing cholinergic transmission; as well as memantine, protecting neurons against glutamate excitotoxicity. Despite ongoing efforts, no new drugs in the treatment of AD have been registered for the last ten years, thus multiple studies have been conducted on genetic factors affecting the efficacy of antidementia pharmacotherapy. The researchers investigate the effects of variants in multiple genes, such as ABCB1, ACE, CHAT, CHRNA7, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, CYP3A7, NR1I2, NR1I3, POR, PPAR, RXR, SLC22A1/2/5, SLC47A1, UGT1A6, UGT1A9 and UGT2B7, associated with numerous pathways: the development of pathological proteins, formation and metabolism of acetylcholine, transport, metabolism and excretion of antidementia drugs and transcription factors regulating the expression of genes responsible for metabolism and transport of drugs. The most promising results have been demonstrated for APOE E4, dementia risk variant, BCHE-K, reduced butyrylcholinesterase activity variant, and CYP2D6 UM, ultrarapid hepatic metabolism. Further studies investigate the possibilities of the development of emerging drugs or genetic editing by CRISPR/Cas9 for causative treatment. : In conclusion, the pharmacogenetic studies on dementia diseases may improve the efficacy of pharmacotherapy in some patients with beneficial genetic variants, at the same time, identifying the carriers of unfavorable alleles, the potential group of novel approaches to the treatment and prevention of dementia.

Download Full-text